Company Info

Elsevier Launches New Journal: Journal of Obsessive-Compulsive and Related Disorders

An international forum for communication and collaboration across clinical and academic fields concerned with obsessive-compulsive disorders

Oxford, March 27, 2012Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, is pleased to announce the launch of a new quarterly journal, Journal of Obsessive-Compulsive and Related Disorders. The first issue of the journal is now available online.

Obsessive-compulsivedisorders (OCD) have intrigued those in the medical and mental health fields for as long as the disorders were first identified by Freud over a century ago. Although crucial advances in understanding and treating OCD have been made over the past half century, important questions remain unanswered regarding the causes of OCD, its true nature, and its boundaries with other seemingly similar mental disorders. Examples are that OCD in elderly and the very young are not well understood, nor do we know how they are influenced by ethnic and cultural factors or how these disorders can be prevented? How can we improve on existing treatments? These and other issues are addressed in the Journal of Obsessive-Compulsive and Related Disorders.

Prof. Jonathan S. Abramowitz of University of North Carolina at Chapel Hill, Editor-in-Chief of the journal said of the launch, “As the founding Editor‐in‐Chief of Journal of Obsessive-Compulsive and Related Disorders,my vision for the journal is to create an international and interdisciplinary forum to foster communication and collaboration across the various clinical and academic fields concerned with Obsessive-compulsive disorders (OCD).”

The Journal of Obsessive-Compulsive and Related Disorders publishes high quality research and clinically-oriented articles dealing with all aspects of obsessive-compulsive disorders (OCD) and related conditions (obsessive-compulsive spectrum disorders: e.g. trichotillomania, hoarding, body dysmorphic disorder).

The first issue is now freely available to view online on SciVerse ScienceDirect.

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

Media contact
Lyndsay Scholefield
Elsevier
+ 44 1865 843825
l.scholefield@elsevier.com